Reviews in this series
| Review . | Authors and affiliations . | Reference . |
|---|---|---|
| The role of chromatin modifiers in normal and malignant hematopoiesis | Jill Butler and Sharon Dent The University of Texas M. D. Anderson Cancer Center Science Park | 1 |
| Mechanisms of epigenetic deregulation in lymphoid neoplasms | Yanwen Jiang, Katerina Hatzi, and Rita Shaknovich Weill Cornell Medical Center | 2 |
| Mutations in epigenetic modifiers in the pathogenesis and therapy of AML | Omar Abdel-Wahab and Ross Levine Memorial Sloan-Kettering Cancer Center | 3 |
| The myelodysplastic syndrome as a prototypical epigenetic disease | Jean-Pierre Issa Fels Institute, Temple University | 4 |
| Epigenetic mechanisms and MLL | Tobias Neff and Scott Armstrong University of Colorado and Memorial Sloan-Kettering Cancer Center | 5 |
| Review . | Authors and affiliations . | Reference . |
|---|---|---|
| The role of chromatin modifiers in normal and malignant hematopoiesis | Jill Butler and Sharon Dent The University of Texas M. D. Anderson Cancer Center Science Park | 1 |
| Mechanisms of epigenetic deregulation in lymphoid neoplasms | Yanwen Jiang, Katerina Hatzi, and Rita Shaknovich Weill Cornell Medical Center | 2 |
| Mutations in epigenetic modifiers in the pathogenesis and therapy of AML | Omar Abdel-Wahab and Ross Levine Memorial Sloan-Kettering Cancer Center | 3 |
| The myelodysplastic syndrome as a prototypical epigenetic disease | Jean-Pierre Issa Fels Institute, Temple University | 4 |
| Epigenetic mechanisms and MLL | Tobias Neff and Scott Armstrong University of Colorado and Memorial Sloan-Kettering Cancer Center | 5 |